There was no significant difference in the age (p = 0.251), gender (p = 0.475), frequency of glioma recurrence (p = 0.845), Ki-67 (p = 0.486), and IDH1 (p = 0.885) mutation status and tumors crossing the midline (p = 0.307) between the training and validation group. The gene discussed is IDH1; the disease is central nervous system cancer.